How to Help Your Patients Find Droxidopa in Stock: A Provider's Guide

Why Patients Struggle to Find Droxidopa

Droxidopa (brand name Northera) is one of only two FDA-approved medications specifically for neurogenic orthostatic hypotension (nOH) — the other being Midodrine. Despite its clinical importance for patients with Parkinson's disease, multiple system atrophy, and pure autonomic failure, finding Droxidopa in stock can be a frustrating experience for patients and providers alike.

The reasons are straightforward: Droxidopa is a specialty medication with a small patient population, limited pharmacy distribution, high retail cost ($2,721 for brand), and mandatory prior authorization for most insurance plans. These factors combine to create a medication that's technically available but practically difficult to obtain quickly.

Current Availability Landscape

In 2026, Droxidopa availability breaks down as follows:

• Brand Northera: Available primarily through specialty pharmacies. Retail chains rarely stock it.
• Generic Droxidopa: Available from multiple manufacturers in 100mg, 200mg, and 300mg capsules. Some retail pharmacies carry generic stock, and prices with coupons start at approximately $36.90.
• Specialty pharmacy networks: Lundbeck's support program routes patients to designated specialty pharmacies that maintain consistent stock.

The good news: generic availability has meaningfully improved access compared to when Northera was the only option.

5 Steps to Help Your Patients Access Droxidopa

Step 1: Prescribe Generic When Possible

Unless there's a clinical reason for brand-name Northera, prescribing generic Droxidopa (with "substitution permitted") gives pharmacies flexibility and patients cost savings. Generic Droxidopa with a GoodRx coupon can be as low as $36.90 versus $2,721 for brand.

Step 2: Initiate Prior Authorization Early

Don't wait for the pharmacy to flag the PA requirement. Submit prior authorization proactively using CoverMyMeds, which connects electronically with most health plans. Key documentation to include:

• Confirmed diagnosis of nOH (ICD-10: G90.3)
• Documented orthostatic blood pressure measurements
• Trial and failure of Midodrine (if step therapy is required)
• Underlying condition (Parkinson's, MSA, PAF)

Step 3: Use Pharmacy-Finding Tools

Direct your patients — or your office staff — to Medfinder for Providers to search for pharmacies with Droxidopa currently in stock. This eliminates the cycle of calling pharmacy after pharmacy that wastes everyone's time.

Step 4: Connect Patients With Financial Assistance

Cost is the most common reason patients abandon Droxidopa prescriptions. Proactively offer:

• Northera Copay Assistance: For commercially insured patients — northera.com
• GoodRx/SingleCare coupons: For generic Droxidopa — prices from $36.90 to $72.04
• Patient assistance programs: NeedyMeds and RxAssist list programs for uninsured or underinsured patients

For a complete breakdown, see our savings guide.

Step 5: Have a Backup Plan

If Droxidopa is unavailable or unaffordable, be ready with alternatives:

• Midodrine — widely available, inexpensive generic, FDA-approved for orthostatic hypotension
• Fludrocortisone — off-label, increases blood volume, very affordable
• Pyridostigmine — off-label, may help with mild nOH symptoms

See our detailed alternatives guide.

Workflow Tips for Your Practice

At the Point of Prescribing

• Check formulary status before the patient leaves the appointment
• Submit PA through CoverMyMeds while the patient is still in office if possible
• Provide a printed list of specialty pharmacies or direct them to Medfinder
• Discuss expected cost and hand off coupon information

Follow-Up Protocol

• Schedule a 1-week follow-up call to confirm the patient obtained the medication
• If PA was denied, appeal promptly with additional documentation
• Track patients on Droxidopa to proactively manage refill gaps

For Patients Switching From Brand to Generic

If patients have been stable on brand Northera, a switch to generic Droxidopa is generally seamless — the active ingredient, dosage forms, and strengths are identical. Monitor blood pressure at the first follow-up after switching to confirm equivalent response.

Understanding the Shortage Context

While Droxidopa is not currently listed on the FDA drug shortage list, its limited distribution and niche patient population create persistent access challenges that function similarly to a shortage. The shortage update for providers covers the broader context.

Final Thoughts

Your patients with neurogenic orthostatic hypotension depend on Droxidopa for their safety and quality of life. The medication exists, the generics exist, and the assistance programs exist — but navigating the system requires proactive effort from the prescribing team. By building PA submission, pharmacy-finding, and financial assistance into your prescribing workflow, you can dramatically reduce the time between writing the prescription and the patient taking their first dose.

For real-time pharmacy availability, visit Medfinder for Providers.